A clear path from research lab to certified knowledge-based biotech.
Lian Gene is built as a long-term scientific company. Our roadmap defines how we move from research excellence today to certified Knowledge-Based Company status and international biotech partnerships tomorrow.
Three pillars driving every phase
Excellence, reproducibility and sustainable innovation underpin every milestone on the roadmap.
Scientific Excellence
Publication-grade research and peer-reviewed methodology in every project.
Reproducibility & Quality
Containerized, version-controlled pipelines aligned with international standards.
Sustainable Innovation
Self-funded R&D plus national & international grant strategy.
Six phases to international scientific impact
- 2024 – 2025
Phase I · Scientific Foundation
Establish research infrastructure, reproducible bioinformatics pipelines, and a peer-reviewed publication portfolio in genomics, cancer genomics and NGS.
- 2025 – 2026
Phase II · Service & Collaboration Growth
Expand genomics & bioinformatics services, build academic and hospital partnerships, and launch national training programs in NGS and multi-omics.
- 2026 – 2027
Phase III · Knowledge-Based Certification
Apply for and obtain certified Knowledge-Based Company status from Iran's Vice-Presidency for Science & Technology, unlocking national R&D incentives.
- 2027 – 2028
Phase IV · Translational & Clinical Products
Develop in-house bioinformatics products, clinical genomics panels and AI-driven precision-medicine pipelines validated for healthcare use.
- 2028 – 2030
Phase V · International Biotech Partnerships
Form strategic alliances with international genomics companies, pharma R&D programs, and global research consortia.
- 2030 +
Phase VI · Iranian Genomics Champion
Become a leading Iranian genomics & bioinformatics company recognized for scientific excellence, innovation and translational healthcare impact.
Join us on the path to a knowledge-based future.
We welcome research, clinical and industrial partners aligned with our long-term vision.